# Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

> **NCT07551349** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 36 (estimated)

## Conditions studied

- Advanced or Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** EB-701/CA9-NK
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07551349
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-04-17
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551349, "Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07551349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*